endOclear Contributes to Decreasing Length of Stay in the ICU A poster entitled The Use of a Unique Mucus Shaver Clearing

Device to Improve Ven tilator Weaning. San Ramon, CA, November 05, 2013 -- A poster entitled The Use of a Unique Mucus Shaver Clearing Device to Improve Ventilator Weaning by researchers at McLaren No rthern Michigan Hospital in Petoskey, Michigan was presented at the CHEST 2013 A nnual Meeting in Chicago, Illinois on October 26-31, 2013. The study shows a dec rease in ventilator days, Intensive Care Unit (ICU) length of stay and total hos pital length of stay by an average of one full day in the group in which endOcle ar was used versus the group that did not use endOclear. In addition, the incidenc e of ventilator associated pneumonia (VAP) also decreased. The observational study, conducted over a two year period, involved 1112 ICU pat ients. All adult patients, age 18 or older, admitted to the ICU, on the ventilat or greater than 24 hours, and who met the general criteria for a sedation holida y and weaning trial were included in the study. Patient ventilator days, ICU len gth of stay, hospital length of stay, and VAP in 2011 were compared with total y ear 2012 patients who had their endotracheal tubes cleared with the endOclear cat heter prior to their weaning trial. 550 cases were reviewed during 2011 and 562 cases in 2012. Prior to the start of endotracheal tube clearing with the endOclear catheter, average ventilator days were 4.3, ICU length of stay was 5.2 days, and hospital length of stay was 9.3 d ays. After introduction of the endOclear protocol in 2012, ventilator days, ICU l ength of stay, and hospital length of stay all decreased by one day. The VAP rat e went from 1.2 per 1000 ventilator days in 2011 to 0 in 2012. The reduction of ventilator days, length of time in the ICU and hospital and number of VAP cases resulted in an estimated savings of $536,710 in 2012. This [McLaren-Northern Michigan hospital] study clearly shows that the endOclear d evice and procedure, when added to a best practice model of care of the ventilat ory patient, results in reduced length of stay, improved patient outcomes and de creased hospital and provider cost. We believe that this will be a huge benefit to the critical care community, stated Dr. Brad Vazales, CEO and CMO of ENDOCLEAR LLC. The study presented on October 30, 2013 at 1:30 PM at the Clinical Resource Cent er (McCormick Place Chicago), concludes that removal of adherent endotracheal tub e secretions with use of the endOclear catheter prior to weaning trials provides both better patient care outcomes and cost savings to the hospital. About ENDOCLEAR: Founded in 2009, ENDOCLEAR LLC is focused on developing novel tools and approach es to previously unaddressed or under-addressed problems in the field of airway management. endOclear with Collection Adapter, first commercialized in 2012 remo ves secretions, biofilm and bacteria from ventilated patient's endotracheal tubes. For more information, please visit http://www.endoclearllc.com. Contact: David Chersky Endoclear Llc 2603 Camino Ramon, Suite 200 San Ramon, CA 94583 855-887-8366 dchersky@endoclearllc.com http://www.endoclearllc.com